Masato Nagatsuka

This inventor holds 13 USPTO granted patents and 1 published patent application, plus 2 CIPO patents and 6 EPO patents. Top assignee: Santen Pharmaceutical Co., Ltd.. Active years: 2011-2017.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Masato Nagatsuka. Retrieved from https://idiyas.com/inventor/masato-nagatsuka

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 13 (Patent Applications = 1)

% Patents Active = 15.4

CIPO Patents = 2

EPO Patents = 6 (Patent Applications = 2)

Average Co-Inventor Count = 5.6

ph-index = 2

Forward Citations = 10(Granted Patents)

Company Filing History:

13 out of 282

Santen Pharmaceutical Co., Ltd.

patents

Years Active: 2011-2017

Loading Chart...

13 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9676703 - Production method for 3,3-dimethyl-3,4-dihydro-1H-quinoxalin-2-one derivative and intermediate for said production method (2017-06-13),

2. 8975256 - 1,2,3,4-tetrahydroquinoxaline compounds having glucocorticoid receptor binding activity (2015-03-10),

3. 8580784 - Method for treating a disease related to the glucocorticoid receptor (2013-11-12),

4. 8569493 - Method for treating a homeostasis-related disease or glaucoma by administering a 1,2,3,4-tetrahyroquinoxaline compound (2013-10-29),

5. 8563551 - Method for preventing or treating a disease related to the glucocorticoid receptor (2013-10-22),

6. 8551991 - 1,2,3,4-tetrahydroquinoxaline derivative having glucocorticoid receptor binding activity (2013-10-08),

7. 8440660 - Method for treating a disease related to the glucocorticoid receptor (2013-05-14),

8. 8420635 - Method for preventing or treating a glucocorticoid receptor-related disease (2013-04-16),

9. 8193187 - 1,2,3,4-tetrahydroquinoxaline compound with a phenyl group substituent having a sulfonic acid ester structure or a sulfonic acid amide structure introduced therein and having glucocorticoid receptor-binding activity (2012-06-05),

10. 8017775 - 1-2-dihydroquinoline derivative having glucocorticoid receptor binding activity (2011-09-13),

11. 8008498 - 1,2-dihydroquinoline derivative having substituted phenylamino lower alkyl group and ester-introduced phenyl group as substituents (2011-08-30),

12. 8008497 - 1,2-dihydroquinoline derivative having (substituted phenyl or substituted heterocyclic) carbonyloxy lower alkyl group and ester-introduced phenyl group as substituents (2011-08-30),

13. 8008496 - 1,2-dihydroquinoline derivative having substituted phenylchalcogeno lower alkyl group and ester-introduced phenyl group as substituents (2011-08-30),

Title: The Innovative Contributions of Masato Nagatsuka

Introduction

Masato Nagatsuka is a prominent inventor based in Ikoma, Japan. He has made significant contributions to the field of pharmaceuticals, holding a total of 13 patents. His work focuses on the development of novel compounds and production methods that have potential industrial applications.

Latest Patents

One of Nagatsuka's latest patents is a production method for 3,3-dimethyl-3,4-dihydro-1H-quinoxalin-2-one derivative and its synthetic intermediate. This innovative method aims to provide a novel approach suitable for the industrial production of the compound. The patent outlines a method for producing a compound represented by a specific formula, detailing various substituents and their configurations. Another notable patent involves 1,2,3,4-tetrahydroquinoxaline compounds that exhibit glucocorticoid receptor binding activity, showcasing his expertise in creating compounds with significant biological activity.

Career Highlights

Nagatsuka is currently employed at Santen Pharmaceutical Co., Ltd., where he continues to advance his research and development efforts. His work has been instrumental in enhancing the pharmaceutical landscape, particularly in the area of innovative drug formulations.

Collaborations

Throughout his career, Nagatsuka has collaborated with esteemed colleagues such as Mamoru Matsuda and Toshiyuki Mori. These partnerships have fostered a collaborative environment that encourages the exchange of ideas and the advancement of innovative solutions.

Conclusion

Masato Nagatsuka's contributions to the field of pharmaceuticals through his patents and collaborative efforts highlight his role as a key innovator. His work continues to influence the development of new compounds and production methods, showcasing the importance of innovation in the pharmaceutical industry.

Profile summary based on public USPTO records.